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6ABBREVIATIONS
ACD - Anemia in Chronic disease
AKI              -        Acute kidney injury
CD - Cluster differentiation
CGN - Chronic  glomerular  nephritis
CIN - Chronic interstitial nephritis
CKD - Chronic Kidney diseases
CKDT         -           Transplant Chronic Kidney disease  stage
CMV - Cytomegalovirus
CRP - C-reactive protein
CVD - Cardio Vascular diseases
DM - Diabetes mellitus
EPO - Erythopoietan
ESAS - Erythropoiesis Stimulating Agents
ESRD - End  Stage Renal Disease
FPN - Ferroportin
PTA - Post Transplant Anema
GFR - Glomerular Filtration Rate
HB - Hemoglobin
HHV - Human Herpes Virus
7hsCRP - High sensitive C- Reactive protein
HUS - Hemolytic uremic syndrome
IL6 - Interleukin 6
ISD - Immunosuppressive drugs
LDH - Lactate dehydrogense
MCH - Mean Corpuscular Hemoglobin
MCHC - Mean Corpuscular Hemoglobin Concentration
MCV - Mean Corpuscular Volume
NAAC - National Anemia Action Council
PCV - Packed Cell Volume
PRCA - Pure Red Cell Aplasia
PSS - Peripheral smear study
RPI - Reticulocyte Production Index
RR - Relative Risk
SHT - Systemic hypertension
TI                -          Total Iron Binding Capacity
TSAT - Transferrin Saturation
TRESAM -Transplant European Survey on Anemia management
TTP  - Thrombotic Thrombocytopenic Purpura
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INTRODUCTION
Anemia of chronic kidney disease is corrected by restored
erythropoietin, synthesized from the graft and is generally corrected by
three months after successful kidney transplantation.
However, it was seen that, a significant number of recipients
continued to be anemic in the post transplant period. Data on the
prevalence of post transplant anemia are limited.
The role of immunosuppressive drugs in causation as well as
aggravation of anemia is well known and although contributory, Our
study aims to enumerate factors other than drugs, which might contribute
to the persistence of anemia in the post transplant period, particularly
erythtopoietin levels in relation to the hemoglobin levels and reticulocyte
counts.
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AIMS AND OBJECTIVES
To asses the incidence of anemia in post renal transplant patients
with successful engraftment, and evaluate the possible factors
contributing to an inappropriate erythropoietin response.
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REVIEW OF LITERATURE
CHRONIC KIDNEY DISEASE
Patients with CKD most often present with nonspecific complaints
or are asymptomatic and are referred to a nephrologist because of
abnormal blood or urine findings. As with AKI, it is important to
establish the cause of CKD. Once this has been accomplished, further
evaluation may be important in order to maximize the potential to
preserve or restore glomerular filtration rate (GFR). Evaluation methods
for CKD are similar to those for AKI; however, specific evaluations
based  on  cause  and  chronicity  are  essential  in  patients  with  CKD.  In
particular, evaluation of cardiovascular risk factors is critical because of
the high rate of cardiovascular complications in CKD.
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TABLE  Risk Factors for Chronic Kidney Disease
Established risk factors
 Age
 Gender (male predilection)
 Race (African American, Hispanic, Native American)
 High blood pressure
 Diabetes mellitus
 Obesity
 Metabolic syndrome
 Proteinuria
 Family history of kidney disease
 Smoking
 Atherosclerosis
 Exposure to nephrotoxins such as analgesics, heavy metals
 Dyslipidemia
 Reduced nephron number at birth
 Recurrent urinary tract infection
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Emerging risk factors
 Oxidative stress
 Elevated plasma homocysteine level
 Anemia
 Prothrombotic factors (e.g., plasminogen inhibitor activator-1)
Prevalence of Chronic Kidney Disease
It is estimated that approximately 20 million Americans have
CKD1. Both the prevalence and the incidence of CKD are increasing. The
most common causes of CKD leading to ESRD are diabetes mellitus,
hypertension, glomerulonephritis, and cystic kidney disease, which
together account for 90% of all new cases of CKD. In the United States,
estimates of prevalence of CKD2 vary from 10 to 20 million, depending
on the definition. Confusion in terminology as well as methods for
defining CKD and its severity have hampered our ability to identify
patients and, therefore, how to approach the problem of CKD. The
Kidney Disease Outcomes Quality Initiative (K/DOQI)5 clinical practice
guidelines for CKD evaluation, classification, and stratification published
by the National Kidney Foundation provide a framework designed to
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address the growing burden of CKD in the United States. The guidelines
emphasize the need for prevention, early diagnosis, and treatment of
CKD. Similar data in Indian population currently limited.
Definition and Staging of Chronic Kidney Disease
CKD is defined as kidney damage with or without decreased GFR,
manifested as either pathologic abnormalities or markers of kidney
damage, including abnormalities in composition of blood or urine,
abnormality renal imaging findings, and a GFR less than 60 mL/min 1.73
m2. This broad definition includes patients with or without symptoms of
kidney disease.
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Staging of Chronic Kidney Disease6
Stage Description
Estimated
GFR[*]
Evaluation Plan
At increased risk
>90 (with
CKD risk
factors)
Screening CKD risk
reduction
1 Kidney damage with
normal or increased
GFR
≥90
Diagnose and treat cause,
slow progression, evaluate
risk of cardiovascular disease
2 Kidney damage with
mild decrease in
GFR
60–89 Estimate progression
3 Moderate decrease in
GFR
IIIa 45-59
IIIb 30-44
Evaluate and treat
complications
4 Severe decrease in
GFR
15–29 Prepare for renal replacement
therapy
5 Kidney failure <15 Initiate renal replacement
therapy
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ESTIMATION OF GLOMERULAR FILTRATION RATE
TABLE   Formulae for Estimating Glomerular Filtration Rate Using
Serum Creatinine and Other Clinical Parameters7
Formula Units Reference
(100/Cr) - 12 if male ml/min/1.73 m2 Jelliffe
(80/Cr) - 7 if female
(Wt · (29.3 - 0.203 · Age)/(Cr · 14.4), if
male
ml/min Mawer
(Wt · (25.3 - 0.175 · Age)/(Cr · 14.4), if
female
(98 - 16 · (Age - 20)/20)/Cr, multiply
by 0.90 if female
ml/min/1.73 m2 Jelliffe
((140 - Age) · (Wt))/(72 · Cr), multiply
by 0.85 if female
ml/min Cockcroft and
Gault
((145 - Age)/Cr) - 3, multiply by 0.85
if female
ml/min/70 kg Hull
(27 - (0.173 · Age))/Cr, if male ml/min Bjornsson
(27 - (0.175 · Age))/Cr, if female
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Formula Units Reference
7.58/(Cr · 0.0884) - 0.103 · Age +
0.096 · Wt - 6.66, if male
ml/min/1.73 m2
(height2)
Walser
6.05/(Cr · 0.0884) - 0.080 · Age +
0.080 · Wt - 4.81, if female
170 · Cr-.999 · Age-.176 · (0.762 if
female) · (1.180 if black) · SUN-.170 ·
Alb.318
ml/min/1.73 m2 Levey
Alb, serum albumin (g/dL); Cr, serum creatinine (mg/dL); SUN, serum
urea nitrogen (mg/dL); Wt, body weight (kg).
MDRD Formula (Modification of Diet in Renal disease)
GFR (ML perminute per 1.73m2 ) =  186 x (SCR)-1.154 x (age)-0.203
 x (0.742 if female)
x (1.210 if African – American)
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DEFINITION AND PREVALENCE OF ANEMIA IN CHRONIC
KIDNEY DISEASE
Anemia  is  a  state  of  deficient  mass  of  red  blood  cells  and
hemoglobin (Hb), resulting in insufficient oxygen delivery to the body's
tissues and organs. The normal values for Hgb and hematocrit (Hct)
depend on gender, race, and other factors. In addition, the reference range
changes in older individuals, with an unexpected increase in the
prevalence of anemia. The National Kidney Foundation's clinical practice
guidelines define anemia12 as a Hgb level less than 13.5 g/dL for adult
men and less than 12.0 g/dL for adult women. For patients living at
altitude, a greater red cell mass is required to maintain tissue oxygen
delivery given the reduced ambient oxygen tension. In addition,
permanent residents at high altitude develop reduced Hgb oxygen
affinity.
TRANSPLANTATION
In general, patients who are not clinically uremic should not be
transplanted until the estimated glomerular filtration rate (eGFR) is ≤15
mL/min or less or at least 20 mL/min13. In the United States, patients can
begin accruing waiting time (which most strongly determines when
22
patients will be allocated a deceased donor kidney) only when the eGFR
is 20 mL/min or less. The rate of progression is also an important
consideration, however. Patient with diabetes, for example, may progress
relatively rapidly, and when it is clear that the patient will require renal
replacement therapy within the next few months, there is no sense in
delaying transplantation if a living donor is available.
Absolute Contraindications
Most absolute contraindications to kidney transplantation are not
irreversible contraindications. Absolute contraindications include life-
threatening infections, cancer, unstable cardiovascular disease (CVD),
and noncompliance. However, infections can often be effectively treated,
cancers can be cured, organs threatened by occlusive arterial disease can
be protected with revascularization procedures, and noncompliant
patients can become compliant. Nevertheless, not every patient with stage
5 chronic kidney disease (CKD) is a transplant candidate.14
In general, patients who would not be expected to survive more
than 2 years with a kidney transplant should probably not undergo
transplantation. If such a patient has a potential living donor, it may not
be ethical to subject that donor to the risk of surgery when expected
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outcomes are poor. If such a patient does not have a potential living
donor, he or she will be unlikely to survive long enough on the waiting
list to receive a deceased donor kidney. The argument can also be made
that a deceased donor kidney may result in greater benefit if it is allocated
to a patient with a life expectancy greater than 2 years than if it is
allocated to someone who is not expected to live that long. Physicians
and transplant centers should inform patients when they are not transplant
candidates, and they should not give the patients false hopes or
expectations. It is not a good practice to place a patient on the waiting list
who is not a good candidate, assuming that the patient will not survive
long enough to be offered a kidney and/or intending to refuse an offered
kidney if it is made available.
TABLE   Transplant Candidate Evaluation to Minimize Infection Risk15
Infection Screening Action
HIV HIV
antibody
Transplant only if stringent conditions
are satisfied
Tuberculosis PPD, chest
x-ray
Consider prophylaxis
Influenza None Vaccinate yearly
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Infection Screening Action
Pneumococcus None Vaccinate at least every 5 yr
HBV HBsAg,
HBsAb
Evaluate further if HBsAg positive,
otherwise vaccinate to achieve and
sustain a HBsAb response
HCV HCV
antibody
Evaluate further if HCV positive
CMV CMV
antibody
Post-transplant prophylaxis
VZV VZV Vaccinate if antibody negative
Childhood
infections
None Measles, mumps, rubella, etc.
CMV, cytomegalovirus; EBV, Epstein-Barr  virus;  HBsAb,  hepatitis  B
surface antibody; HBsAg, hepatitis B surface antigen; HBV, hepatitis B
virus; HCV, hepatitis C virus; HIV, human immunodeficiency virus;
PPD, purified protein derivative; VZV, varicella zoster virus.
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ANAEMIA IN RENAL TRANSPLANT PATIENTS
Anemia is relatively common after transplantation. Regular
screening and careful evaluation of the multiple factors that can
contribute to anemia after transplantation are recommended.
Prevalence of anemia33 in transplant CKD clearly is associated
with the level of allograft function. However, a number of other factors
unique to transplant recipients may contribute to the development of
PTA. There is little information regarding the association of anemia with
either graft or patient outcomes. Similarly, there is limited information to
suggest that the response to treatment with ESAs differs between patients
with  CKD  with  and  without  a  transplant.  Although  there  are  reports  of
increased delayed graft function and hypertension with the use of ESAs34,
there is insufficient evidence to suggest that these agents should not be
used in either the immediate posttransplantation or late
posttransplantation period. Conversely, with the existing information, it is
recommended that treatment guidelines for management of anemia in the
general CKD population be followed in the transplant population.
Transplant  recipients  are  a  subgroup  of  patients  with  CKD  with
unique considerations with regard to anemia management.
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Transplant recipients have variable exposure to CKD before
transplantation. Patients with functioning transplants include preemptive
transplant recipients, recipients with variable exposure to dialysis, and
repeat and multiorgan transplant recipients. Consequently, the burden of
comorbid disease varies among transplant recipients, and this may have
important implications for the severity and management of anemia.
PREVALENCE
There is no accepted definition of anemia in transplant recipients,
and variable definitions are used in the literature. A second important
consideration is that the prevalence of anemia is dependent on the time of
observation after transplantation.
During the early post transplantation period, arbitrarily defined as
the first 6 months after transplantation, anemia of varying degrees is very
common. The prevalence35 and degree of anemia during this period are
dependent on the pre transplantation Hb level, amount of perioperative
blood loss, frequency of blood draws, iron depletion, persistence of
uremia, endogenous erythropoietin levels, erythropoietin
responsiveness, and exposure to immunosuppressive agents.
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The time course of erythropoiesis after transplantation has been
studied by a number of investigators, and reviews on this subject are
available. A transient early peak of erythropoietin is detectable within the
first 24 hours after transplantation, particularly in patients with delayed
graft function, and is not associated with a measurable increase in Hb
level. Within the first number of days after successful transplantation, a
smaller, more sustained erythropoietin peak is detectable. This peak is
associated with the subsequent onset of erythropoiesis and recovery of
renal anemia during the next several months after transplantation.
(Ref : K/DOQI clinical
practical guide lines for ckd)
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ERYTHROPOIESIS AND PRODUCTION OF EPO BY
THE RENAL ALLOGRAFT
Successful renal transplantation results in the normalization of
renal function and resolution of anemia of CKD.  In contrast to non renal
forms of anemia in which serum EPO levels are inversely correlated with
the levels of Hb, with anemia of renal disease, the lower the EPO levels,
the worse the anemia.  Therefore, the early resolution of anemia in post
transplantation is because of the normal mechanisms that regulate the
production  and  secretion  of  EPO.   The  events  that  result  in  the
normalization of  erythropoiesis  and the early recovery of  anemia can be
summarized as follows:
1. An early rise in  EPO secretion starts within the first 24 hours after
transplantation43 44.  This initial peak is transient and ineffective in
generating normal eruthropoiesis.
2. After the first week post transplant, a smaller and more sustained peak
of EPO production occurs.  This second peak is associated with the
subsequent onset of erythropoiesis and recovery of anemia over the
next 2 to 3 months 43 44
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3. By 10 weeks after transplant, serum EPO concentrations should reach
100% of the expected levels in individuals with normal functioning
grafts.
PATHOPHYSIOLOGY
A number of factors may cause PTA; some are shared with other
patients with CKD, whereas others are unique to transplant recipients.
Factors Shared With Other Patients With CKD
In general, the evaluation of PTA should parallel that among non
transplantation patients with CKD. The discussion regarding factors
contributing  to  PTA  that  are  shared  with  other  patients  with  CKD  is
limited to the most common considerations and to unique considerations
in the transplantation setting.
Kidney Function
Level of allograft function is clearly an important determinant of
PTA. In the TRESAM (Transplant European Survey on Anemia
Management, there was a strong association of anemia with kidney
transplant function. Of 904 patients with an SCr level greater than 2
mg/dL, 60.1% were anemic compared with 29% of those with an SCr less
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than 2 mg/dL, In a single-center study of 459 patients at least 6 months
after transplantation, prevalences of anemia, defined as an Hb level less
than 11 g/dL, among patients with CKD stages 1, 2, 3, 4, and 5 were 0%,
2.9%, 6.6%, 27%, and 33%, respectively.
The association of level of allograft function with Hb level appears
to vary with the time of observation after transplantation. One study
found that, among patients with an eGFR greater than 90 mL/min/1.73
m2,  11%  and  7%  of  patients  had  anemia  at  6  and  12  months  after
transplantation, whereas among patients with an eGFR less than 30
mL/min/1.73 m2, at 6 and 12 months after transplantation, 60% and 76%
were anemic, respectively. These findings suggest that factors in addition
to level of allograft function may be important determinants of anemia,
particularly during the early post transplantation period.
Whether the association between anemia and level of kidney
function differs in patients with CKD who did and did not undergo
transplantation is uncertain. In a study of 23 renal transplant recipients
with stable kidney function, 12 anemic patients were compared with the
11 non anemic control patients.  Of the 12 anemic patients, 10 had low
erythropoietin levels suggestive of erythropoietin deficiency, 2 patients
had higher than anticipated erythropoietin levels suggestive of
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erythropoietin resistance, whereas 5 of 11 non anemic control patients
had higher than expected erythropoietin levels. Thus, there appears to be
significant variation in erythropoietin production and responsiveness in
transplant recipients, which may alter the association between kidney
function and anemia in transplant recipients. Other clinically evident
examples of the dissociation between Hb level and kidney function in
transplant recipients include posttransplantation erythrocytosis and, as in
non transplantation patients with CKD, the lower incidence of anemia
among transplant recipients with polycystic kidney disease.
IRON DEFICIENCY
Iron deficiency may be an important factor in the development of
anemia after transplantation. There is limited information regarding the
prevalence of iron deficiency after transplantation. In a cross-sectional
study of 438 prevalent transplant recipients, the prevalence of iron
deficiency, defined45 as a percentage of hypochromic red blood cells of
2.5% or greater, was 20.1%. In another study46 of 439 prevalent
transplant recipients, 41% of patients had a TSAT less than 20%, whereas
44% had a ferritin level less than 100 ng/mL.
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The prevalence of iron deficiency may be greater in the early
transplantation period because of low pre transplantation iron stores in
dialysis patients and increased iron utilization with the onset of
erythropoiesis after successful transplantation. In one study, 24 of 51
patients were found to be iron deficient in the early post transplantation
period. In a prospective study of 112 transplant recipients, serum ferritin
levels decreased from 109.6 µg/L (range- 21 to 4,420 µg/L) at
transplantation to 54.9 µg/L (range- 2 to 1,516 µg/L) at 6 months after
transplantation.
Transplant-Specific Factors
Acute Rejection
Early acute rejection is reported to cause a sharp decrease in
erythropoietin production and anemia. Insights into the molecular
mechanisms involved in the development of anemia during allograft
rejection have been elucidated from gene expression studies. Among 4
pediatric renal allograft recipients with acute rejection and anemia, a
cluster of 11 genes involved in Hb transcription and synthesis, iron and
folate binding, and transport were found to be downregulated. An
additional mechanism for the development of anemia during rejection is
thrombotic microangiopathy, which may develop during episodes of
severe vascular rejection.
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MEDICATIONS
IMMUNOSUPPRESSIVE MEDICATIONS.
The use of myelosuppressive medications for immunosuppression
and antiviral prophylaxis or treatment may be important factors in the
development of anemia after transplantation. Azathioprine and
mycophenolate mofetil are myelosuppressive; therefore, anemia caused
by these drugs often is associated with leukopenia and/or
thrombocytopenia. (Ref – JASN – Anemia after kidney transplantation)
Very rarely, PRCA may occur with the use of these drugs.
Calcineurin inhibitors infrequently are associated with anemia. The
most common mechanism for PTA associated with the use of calcineurin
inhibitors is microangiopathy and hemolysis. The immunosuppressant
OKT3 also has been associated with hemolytic uremic syndrome (HUS)
and microangiopathy47.
Anemia was a significant Adverse effect in a phase III trial in
which sirolimus was administered with cyclosporine and
corticosteroids. A group reviewed the 10-year experience with sirolimus
and reported a dose-dependent association of anemia with the drug in
phase  I  and  II  trials.  The  association  of  sirolimus  with  anemia  also
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recently was shown in single-center analyses. Sirolimus may inhibit
erythropoiesis by interfering with intracellular signaling pathways
normally activated after the binding of erythropoietin to its receptor, and
sirolimus also may be associated with thrombotic microangiopathy.
ANTIVIRAL AND ANTIMICROBIAL MEDICATIONS.
A number of commonly used antivirals and antibiotics may cause
anemia, including ganciclovir and trimethoprim-sulfamethoxazole.
Angiotensin-converting enzyme inhibitors and angiotensin II
receptor antagonists.
Angiotensin-converting enzyme (ACE) inhibitors and angiotensin
receptor blockers (ARBs) may be associated with PTA48. Anemic patients
in the TRESAM had higher odds of receiving ACE inhibitors or ARBs
(odds ratio, 1.55; 95% CI, 1.34 to 1.80; P < 0.001). In a single-center
retrospective study, a significant curvilinear dose-response relationship
was identified between ACE-inhibitor dose and Hct. The underlying
mechanisms are complex and include inhibition of endogenous
erythropoietin production, inhibition of angiotensin II–mediated
stimulation of red blood cell precursors, and the generation of an
erythropoiesis-inhibiting protein by ACE inhibitors.
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INFECTIONS AND MALIGNANCY
Anemia may be a feature of cytomegalovirus (CMV) infection.
Parvovirus  B19 infection  has  been  reported  in  transplant  recipients  with
anemia and may cause PRCA49.
Hemophagocytic syndrome (HPS) is a rare cause of PTA. The
syndrome often is caused by infectious or neoplastic disease and is
defined by bone marrow and organ infiltration by activated non-
malignant macrophages that phagocytose red blood cells. A retrospective
analysis of 17 cases among deceased donor transplant recipients showed
that the syndrome developed after a median duration of 52 days after
transplantation. Fever was present in all patients and hepatosplenomegaly
was  present  in  9  of  17  patients.  Eleven  patients  had  received  anti
lymphocyte globulins in the 3 months before presentation. In 9 patients,
HPS was related to viral infections (CMV, Epstein-Barr virus, and human
heprus virus 6 and 8); other infections included tuberculosis,
toxoplasmosis, and Pneumocystis carinii pneumoniae. Post
transplantation lymphoproliferative disease was present in 2 patients. The
syndrome has a poor prognosis—8 of 17 patients died despite the use of
anti-infectious therapy and tapering of immunosuppression.
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HEMOLYTIC UREMIC SYNDROME
HUS may recur after transplantation and can result in allograft loss.
De novo HUS may occur associated with the use of cyclosporine,
tacrolimus, or OKT3. The syndrome also has been associated with CMV
and influenza A infection in transplant recipients. The possibility that
erythropoietic agents may be beneficial in patients with HUS after
transplantation is suggested by observations from the non transplantation
population. Plasma from approximately 75% of patients with sporadic
thrombotic thrombocytopenic purpura (TTP)/HUS induces apoptosis in
cultured microvascular endothelial cells. The mechanism appears to be
linked to induction of Fas (CD95) on cultured endothelial cells because
the erythropoietin receptor is expressed on vascular endothelial
cells. Erythropoietin prevents lipopolysaccharide-induced apoptosis in
cultured endothelial cells, suggesting that erythropoietin may have a
protective effect and may be of therapeutic benefit in TTP/HUS in the
non transplantation setting. The use of ESAs after transplantation in
patients with HUS warrants further study50.
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Hemolytic Anemia Associated With Minor Blood Group A, Group B,
Group O Incompatibility
Blood group A recipients receiving transplants from blood group O
donors or blood group AB recipients receiving transplants from either
group A or B donors may develop evidence of hemolysis caused by anti-
A or anti-B antibodies of the donor or from autoantibodies produced by
passenger lymphocytes.
CLINICAL OUTCOMES
There is only limited information regarding the association of
anemia with clinical outcomes in transplant recipients.
Transplant recipients are known to be at increased risk for
cardiovascular events, particularly during the perioperative period. In a
single-center study of 404 transplant recipients with diabetes between
1997 and 2000, patients with at least 1 monthly Hct level less than 30%
during the first 6 months after transplantation had a significantly greater
incidence of cardiovascular events compared with patients with monthly
Hct values greater than 30%. In a multivariate analysis that also included
patient age and history of ischemic heart disease (IHD), an increase in
monthly Hct to greater than 30% was associated with a significantly
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lower risk for cardiovascular events (RR, 0.65; 95% CI, 0.33 to 0.91; P =
0.02).
Among long-term transplant recipients, there is limited information
regarding the association of anemia with adverse cardiovascular events.
In  a  retrospective  study  of  638  transplant  recipients  between  1969  and
1999 who were alive and free of cardiac disease 1 year after
transplantation, lower Hb levels were associated with an increased risk
for de novo Congestive heart failure (RR, 1.24/10-g/dL decrease in Hb;
95% CI, 1.10 to 1.39; P = 0.001). In a follow-up study, anemia was
associated with increase in left ventricular mass (as measured by Cornell
voltage on electrocardiogram) during the first 5 years after
transplantation.
In a recent study, 438 prevalent transplant recipients were followed
up for a median of 7.8 years. Laboratory parameters obtained during a 4-
week enrollment period in 1995 were tested for their association with all-
cause mortality and allograft failure. The investigators did not identify an
association between anemia (Hb < 10 g/dL) and all-cause mortality or
graft survival. Compared with patients with hypochromic red blood cells
less than 5%, patients with hypochromic red blood cells greater than 10%
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had an RR of 2.06 for all-cause mortality (95% CI, 1.12 to 3.79; P =
0.02).
In a retrospective single-center study of resource utilization among
220 kidney transplant recipients, patients with a higher Hct had a
decreased risk for hospitalization (RR, 0.95/1% increase in Hct; 95% CI,
0.92 to 0.98; P < 0.001)
Post transplantation Failure
Patients with allograft failure have a high mortality that is related
primarily to CVD. The management of anemia among patients with
failing allografts is suboptimal. In a study of patients initiating dialysis
therapy after transplant failure in the United States between 1995 and
1998, mean Hct was 27.5% ± 5.9% and 67% had an Hct less than 30%.
The use of ESAs at the time of dialysis therapy initiation was infrequent
(35%). Anemia management may be more difficult in patients with
transplant failure because of the presence of chronic inflammation and
relative resistance to ESAs.
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MATERIALS AND METHODS
Study Design:
Prospective Cohort Study
Study Populations:
Post Renal Transplant Patients with anemia
Inclusion Criteria:
·   Hb levels of < 13g/dl – male, < 12g/dl – female
·   Patients with minimum of 6 months after transplant ,as the
optimum erythropoietin response is observed not earlier
than 6 months after  transplant.  The selected patients  didnot
have the expected Hb increment 6 months after the
transplant [ pre-transplant and post-transplant Hb – P value
– 0.0002]
MEAN
HB P-VALUE
PRETRANSPLANT 10.0225
0.0002
POST
TRANSPLANT 8.8075
42
Exclusion Criteria:
Transplant period – < 6 months  Graft failure
Ethical Clearance :
Obtained:
Informed Consent:
Obtained from all patients.
Methodology:
A total of 40 patients were observed in the nephrology OPD over a
period of 12 months (April 2009 to Mar 2010) according to the above
criteria and were included in the study.
A questionnaire prepared, noted the following
- The age at transplantation.
- Likely cause of renal failure
- Comorbid illness
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- Transplant related information such as kidney donor,
Pretransplant Hb, immunosuppressive drugs used, use of
induction therpy, bloodloss, blood transfusion, occurrence of
delayed graft function, infection – CMV & TB.
Clinical examination included a detailed examination from head to
foot, examination of cardiac, respiratory, GI tract, and nervous systems,
per rectal and per vaginal examination (in females) were done.
         The above data were procured from every patient included in the
study and analysis was made with the following.
· GFR [ index of renal function ] with the Hb levels
· GFR with serum erythropoietin level
· Erythropoietin with Hb level
The analysis was directed towards evaluating a possible, persisting
inflammatory response interfering with erythropoietin regulated
hemoglobinization of erythrocytes.
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Laboratory Investigations:
Complete blood count, including red cell indices, ESR, peripheral
smear study, reticulocyte count,
· Serum iron, TIBC,
· Serum creatinine, GFR,
· CRP, LDH
· Erythropoietin.
Medications other than immunosuppressives such as Gancyclovir,
ACE inhibitors, ARBs, use of erythropoietins were recorded.
S.NO PARAMETER METHOD
1 Complete blood count Automated flow cytometry
2 ESR Westegren method
3 Serum Iron Photocolorimetric method
4 TIBC Photocolorimetric method
5 CRP Latex Agglutination method
6 LDH UV kinetic methods
7
Erythropoietin Chemiluminescence
Immunassay
8 GFR Cockcroft gault formula
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Statistical  Analysis:
Data analysis was done with use of SPSS, version 13. Descriptive
statistics were used to calculate the frequency, mean, and standard
deviation. To examine the linear trend of the proportions, trend chi-square
was used and to find the test of association chi-square was computed.
Financial support:
Nil
Conflicts of interest:
None
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NORMAL VALUES
Hemoglobin M:13.3 – 16.2gms% F:12.0-
15.8gms
PCV M:38.8 – 46.4 35.4 – 44.4
Total Count 3.54 – 9.06 x 103/ mm3
Platelet Count 165 – 415 x 103 / mm3
MCV 80 – 100 fL
MCHC 32.3 – 35.9g/dL
MCH 26.7 – 31.9 pg/cell
ESR M : 0 – 15 mm/hr
Reticulocyte count M : 0.8 – 2.3%
LDH 115-221U/L
CRP 0.8 – 3.1 mg/L
SR.Iron 41-141microg/dl
TIBC 251-406microg/dl
SR.Erythropoietin 3.7-29.5microIU/ml
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STUDY POPULATION CHARACTERISTICS
TABLE 1:SEX DISTRIBUTION
PATIENTS NO OFPTS PERCENTAGE
MALE 31 77%
FEMALE 9 23%
FIGURE:1 SEX WISE DISTRIBUTION
· Our study included a total of 40 patients showing the incidence of
male, female ratio
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TABLE :2 AGE DISTRIBUTION OF STUDY POPULATION
AGE NO OFPTS PERCENTAGE
21-30 17 42.50%
31-40 16 40%
41-50 7 17.50%
FIGURE :2 DISTRIBUTION OF PATIENTS BASED ON AGE
· Patients from 21-50yrs were included in our study with 17 patients
in the 21-30yrs[42.5%]
· 16 patients in the 31 -40 yrs[ 40%] and 7 patients in the 41-
50yrs[17.5%]
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TABLE-3:DISEASE DISTRIBUTION IN STUDY POPULATION
DISEASES NO.OF.PTS PERCENTAGE
CGN 22 55%
CIN 8 20%
DM 8 20%
SHT 1 2.50%
OTHERS 1 2.50%
FIGURE-3: DISEASE DISTRIBUTION IN STUDY POPULATION
The diseases leading to esrd in the study included
· CGN- 55%
· CIN-20 %
· DM-20%,
· SHT-2.5%,
· OTHERS-2.5%
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TABLE-4:SR CREATININE LEVEL IN STUDY POPULATION
SR.CREATININE NO OFPTS PERCENTAGE
1-1.29 23 57.50%
1.3-1.9 10 25%
2.0-3.0 7 17.50%
FIGURE 4 : SR CREATININE  DISTRIBUTION IN STUDY
POPULATION
· In our study 23 patients[ 57.5%] maintained the sr creatinine level
within 1-1.29,
· 17 patients [42.5%] maintainingthe sr creatinine level within 1.3-
3mg/dl.
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TABLE-5:GFR  IN STUDY POPULATION
GFR ML/M/1.73 M NO OFPTS PERCENTAGE
60-89 13 32.50%
30-59 27 67.50%
FIGURE-5:  GFR IN STUDY POPULATION
· GFR as a index of renal function indicating that 27 patients
[67.5%] were in stage 2 ckdt ,
· 13 patients [32.5%] were in the stage 3 ckd
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TABLE-6:HEMOGLOBN IN STUDY POPULATION
MEAN HB P-VALUE
PRETRANSPLANT 10.0225
0.0002
POST TRANSPLANT 8.8075
FIGURE-6: HEMOGLOBIN DISTRIBUTION
 IN STUDY POPULATION
· The patients selected had PRE TRANSPLANT mean Hb of
10.0225gm/dl and post transplant mean Hb of  8.8075 gm/dl with p
value of  0.0002, indicating an appropriate patient  selection.
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TABLE -7: CORRELATION OF HB WITH GFR
Correlation Coefficients Matrix
Sample size 40
Critical
value (5%) 2.0244
GFR HB
GFR
Pearson Correlation
Coefficient 1
R Standard Error
T
p-value
H0 (5%)
HB
Pearson Correlation
Coefficient -0.0257 1
R Standard Error 0.0263
T -0.1585
p-value 0.8749
H0 (5%) accepted
R
Variable vs.
Variable R
HB vs. GFR -0.0257
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DISDRIBUTION OF HB ACCORDING TO GFR
· Hb level of study patients were compared with the GFR [post
transplant]. Despite the significant return of renal function
[stage2,3ckdt],the expected Hb increment was not noted, with the p
value of 0.8749 .
GFR
9080706050403020
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10
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2
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TABLE 8: DISTRIBUTIONOF SR IRON IN STUDY
POPULATION
SR IRON NO  OFPTS PERCENTAGE
<50 6 15%
51-150 29 72.50%
>151 4 10%
FIGURE 8: DISTRIBUTION OF SR IRON IN STUDY POPULATION
· The Serum iron status in 29 patients [72.5%] was within normal
range. Only 6 patients had serum iron levels of <50 micro
gram/dl[17.5%]. it is probably contributing to the persistence of
anemia. About 4 patients [10%] had high serum iron level. In our
study, serum iron level didnot correlate with improving GFR.
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TABLE 9 : CORRELATION OF IRON WITH GFR
Sample size 40 Critical value(5%) 2.0244
GFR IRON
GFR Pearson CorrelationCoefficient 1.
R Standard Error
t
p-value
H0 (5%)
IRON Pearson CorrelationCoefficient -0.2441 1.
R Standard Error 0.0247
t -1.5517
p-value 0.129
H0 (5%) accepted
R
Variable vs.
Variable R
IRON vs. GFR -0.2441
· Iron  level  of  study  patients  were  compared  with  the  GFR  [post
transplant] with p value of 0.129
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TABLE 10 : ERYTHROPOIETIN (ENDOGENOUS) LEVEL IN
STUDY POPULATION
ERYTHROPOIETIN PERCENTAGE
4.5-29 27.50%
30-60 27.50%
61-120 27.50%
121-200 17.50%
FIGURE 10 : ERYTHROPOIETIN (ENDOGENOUS) LEVEL IN
STUDY POPULATION
· In our study 27.5% patients had normal erythropoietin level, the
others had increased erythropoietin level.
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TABLE-11 :CORRELATION OF ERYTHROPOIETIN WITH GFR
Correlation Coefficients Matrix
Sample size
40
Critical
value
(5%)
2.0244
GFR EPO
GFR
Pearson Correlation
Coefficient 1
R Standard Error
t
p-value
H0 (5%)
EPO
Pearson Correlation
Coefficient 0.4277 1
R Standard Error 0.0215
t 2.9172
p-value 0.0059
H0 (5%) rejected
R
Variable vs.
Variable R
EPO vs.
GFR 0.4277
· Serum erythropoietin level showed an increase commensurate with
return of glomerular function.with the p value of o.0059 which
statistically significant.
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TABLE 12: DISTRIBUTION OF SERUM LDH IN STUDY
POPULATION
SR LDH NO OF PTS
>230 40
FIGURE 12 : DISTRIBUTION OF SERUM LDH IN STUDY
POPULATION
· Sr LDH was above normal in all the 40 patients in our study
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TABLE 13 : CORRELATION OF SERUM LDH WITH GFR
Correlation Coefficients Matrix
Sample size 40
Critical value
(5%) 2.0244
GFR LDH
GFR
Pearson Correlation
Coefficient 1.
R Standard Error
t
p-value
H0 (5%)
LDH
Pearson Correlation
Coefficient 0.242 1.
R Standard Error 0.0254
t 1.5372
p-value 0.1325
H0 (5%) accepted
R
Variable vs.
Variable R
LDH vs. GFR 0.242
· There was no correlation of sr LDH value with an improving
GFR.with p value of 0.1325.
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TABLE 14 : CORRELATION OF SERUM LDH WITH HB
Correlation Coefficients Matrix
Sample size 39
Critical value
(5%) 2.0262
LDH HB
LDH
Pearson Correlation
Coefficient 1.
R Standard Error
t
p-value
H0 (5%)
HB
Pearson Correlation
Coefficient 0.0508 1.
R Standard Error 0.027
t 0.3093
p-value 0.7589
H0 (5%) accepted
R
Variable vs.
Variable R
HB vs. LDH 0.0508
· The  high  LDH  value  in  response  to  low  Hb  could  indicate  low
grade hemolysis, but was not supported by an appropriate
reticulocyte response. With the  p value of 0.7589 is therefore
statistically not significant.
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TABLE 15 : CORRELATION OF TIBC WITH GFR
Correlation Coefficients Matrix
Sample size 40
Critical value
(5%) 2.0244
GFR TIBC
GFR
Pearson Correlation
Coefficient 1.
R Standard Error
t
p-value
H0 (5%)
TIBC
Pearson Correlation
Coefficient 0.0594 1.
R Standard Error 0.0262
t 0.3667
p-value 0.7159
H0 (5%) accepted
R
Variable vs.
Variable R
TIBC vs. GFR 0.0594
· TIBC which include ferritin and transferrin, reflects not only
percentage saturation but also the response to any underlying
chronic inflammation as an acute phase reactant .The TIBC level
also didnot show any correlation with improving gfr. With p value
of 0.7159 .
TABLE 16 : IRON –TIBC CORRELATION
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SR TIBC NO OF PTS PERCENTAGE
300-360 4 10%
361-550 10 25%
551-750 10 25%
750-1200 13 40%
90% Patients had significantly high TIBC despite high serum iron
levels indicating
· In effective feedback
· Elevated ferritin & transferrin as an acute phase reactant
TABLE 17 : HB -IRON –TIBC CORRELATION
SRNO HB SR.IRON TIBC
1 7.3 120 1012
2 9.5 102 566
3 10 160 108
4 2.8 150 113
5 8 126 690
6 8.2 138 773
7 9.8 191 475
8 10 128 983
9 9.6 135 968
10 12 161 953
11 10 105 743
12 9 116 905
13 9 111 614
14 10 163 724
15 11 130 565
· From the above table it is evident that high SR TIBClevel persisted
in patients with high serum iron levels. Among the 12 patients, 6
[50%] of them continue to have low Hb level <10 gm%, The
SERUM IRON, TIBC levels reflecting the pattern observed in
anemia of chronic disease.
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TABLE 18 : HB  -MCV –IRON  CORRELATION
SR NO HB MCV SR IRON
1 6.9 75 160
2 11 79 71
3 8 74 42.7
4 7 72 70
5 11 78 128
· Correlation between HB/MCV/SR IRON was analysed it was
found that in patient with microcytosis [mcv<80],sr iron
significantly elevated in 2 of 5 patients [40%] indicating alternate
mechanism of ineffective erythropoiesis.
TABLE 19 : MCV LEVEL IN STUDY POPULATION
mcv CHARECTERSTICS no of pts percentage
<80 microcytic 5 12.50%
80-100 normocytic 32 80%
>100 macrocytic 3 7.50%
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FIGURE 19 : MCV LEVEL IN STUDY POPULATION
· Mcv analysis in the 40 patients showed   Microcytosis in [12.5%] ,
Normocytosis in [80%] , Macrocytosis in [7.5%]
· 32 patients had normocytic anemia ;out of this 17 had CGN, 7
patient had CIN.7 patient had DM 1 patient had SHT [25 -62.5%],
· In Patients with CGN,DM ,SHT the basic pathology may still play
a  role  in  the  post  transplant  period,   inciting  a  renal  compromise
and erythropoietin resistance.
· CRP –The c reactive protein value of 40 patient included in our
study was normal, however, the sensitivity of CRP being low ,this
particular parameter could not be taken into consideration for
analysis. hs CRP being a more sensitive parameter would be of
greater significance.
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DISCUSSION
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DISCUSSION
Anemia in the post renal transplant setting is a relatively common
feature.  This has been a subject of analysis in various transplant centres
only in recent times.  This is probably because the problem of anemia and
its refractoriness to treatment (erythropoietin), despite satisfactory
allograft function, is being increasingly appreciated in surviving patients.
Number of other factors may contribute to this anemia.  Known factors
like delayed graft function and hypertension were not common in patients
taken up for this study.
The  studies  quoted  by  yorgin  et  al.  Tresam  found  8.5%  severe
Anemia, in our study found 35% (<11gms) of patients severely anemic44.
37.5% patients had serum iron of less than 75 mgs %, NAAC
Review showed prevalence of iron deficiency 21.1% in one study, 41% in
other study. The iron depletion in the immediate post transplant patient
due to dialysis or rapid erythropoietin response could not be considered
as a contributing factors.  Among 4 female patients 2 had abnormal
uterine bleeding with anovulatory cycles.  2 patients had recurrent
diarrohea with features suggestive of malabsorption, the others showed
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appreciable mild response to oral iron, indicating possible nutritional
deficiency.
Among 3 patients (7.5%) presenting with macrocytic anemia.  One
was a chronic alchoholic in the pre transplant period, two other female
patients had co-existing hypothyroidism and were on thyroxine
substitution.
The major chunk of our study patients presented with normocytic
anemia. In these patients that the possibility of other factor, contributing
to  the  anemia  had  to  be  deciphered.   The  mean  post  transplant  GFR
achieved 6 months after transplant in our study was 54.92 ml/m/1.73m2
indicating that 32.5% were in stage 2 and 67.5% were in stage 3 CKDT.
The potential risk of decreasing renal function with time, when compared
to non-transplanted individuals, clearly sets these individual at a higher
risk of anemia.  The focus therefore need to shift towards maintaining
long-term graft function. Date from UK renal registry show successful
management of anemia in patients with CKD stage 4T & 5T.
72.5% of patients showed an increased erythropoietin level
indicating the healthy allograft response, however, this function did not
reflect in the hemoglobin level.  This indicated that other factors could be
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impeding the normal hematopoietic response to erythropoietin.  An
attempt to identify an underlying chronic inflammatory activity,  -
persisting  pre  transplant  disease  activity,    -   or  post  transplant  chronic
immunoreactivity,  -  was made while analysing these patients.
Above  90%  of  patients  in  the  3rd,  4th decade, presented  with
chronic glomerular disease and chronic interstitial nephritis as the cause
for the CKD.  Diseases contributing to CKD in the elderly like DM, SHT
contributed to 10% only.  Good number of them required concommitant
treatment of the precipitating disease process which could also contribute
to the altered internal milleu.
The following features supported our suspicion of a persistent
chronic inflammatory state contributing to the anemia.
1. As already indicated the GFR of the patient had improved to a
functional  status  of  statge  2,  3  CKDT.   A  commensurate  Hb
increment however, was not noted.  P value - 0.8749.
2. The erythropoietin level showed an increase commensurate with
the return of glomerular function. (P value – 0.0059).  However,
similar improvement in Hb was not observed.
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3. The LDH was increased to appreciable level in most of the
patients.  A hemolytic response probably contributing to this
increase  was  not  supported  in  any  of  our  patients  with  an
appreciable reticulocyte count increase.  The LDH increase,
therefore probably reflects the persisting kidney disease /
inflammatory activity.
4. Total iron binding capacity showed an appreciable increase, higher
than  what one would expect for a given hemoglobin level.  TIBC
include ferritin and transferrin both of which can respond as acute
phase reactants. The significant increase noted in our study
probably reflects the response to underlying chronic disease
activity.
5. CRP value in our study was within normal range in all our patients.
A more sensitive hs CRP evaluation would have reflected any
coexisting inflammatory activity.  Therefore serum LDH and TIBC
were analysed in this direction ( Ref: AbrahamN.CartyR, DufourD,
Henry’s clinical diagnosis and management by laboratory methods
chapt. 20). Other studies evaluating post renal transplant anemia
has shown the need for IL6 and hepcidin level to indicate or
exclude a chronic inflammatory state.
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6. Anemia and inflammation
Ø   ACD is observed in many condition associated with chronic
inflammation. This normocytic (or moderately microcytic),
normochromic anemia is characterised by low serum iron levels,
low-normal  TF  saturation,  and  an  elevated  ferritinemia.   In
contrast to iron deficiency anemia patients are not responsive to
iron supply.
Ø   Both  cytokines  (such  as  IL-I,  IL-6,  LPS  and  TNFα)  and
hepcidin are implicated in iron metabolism disturbances
characteristic of ACD. During chronic inflammation,
erythrophagocytosis rate is increased as a result of macrophage
activation and cytokine induced red blood cell membrane
alterations, an effect mostly driven by TNFα.  This result is
reduced RBC lifespan.  In addition, iron efflux from macrophages
is restricted, as a consequence of various events: downregulation
of FPN gene transcription, increased expression of hepcidin,
which reduces the amount of FPN present at the cell surface, and
finally activation of ferritin gene transcription.  All of these
effects are mediated by pro-inflammatory cytokines and concur to
induce sequestration of iron into macrophages and reduction of
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plasma iron or hypoferremia.  This diversion of iron from the
circulation into storage sites is associated with subsequent
limitation of the availability of iron for erythroid progenitor cells
and onset of iron-restricted erythropoiesis.  The latter effect is
moreover amplified by pro-inflammatory cytokines (in particular
IL-I and TNFα), which inhibit erythropoietin synthesis and
proliferation of erythroid progenitor. (Ref : Recycling iron in
Normal and Pathological States – Carole Beaumont and
Constance Delaby).  (Seminars in Hematology, Vol 46, No.4,
October 2009, pp 328-338).
Ø    Therefore more comprehensive analysis of anemia of chronic
disease with persisting Inflammation could be made with
evaluation of Inflammatory cytokine particularly IL6 and
hepcidin.
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CONCLUSION
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CONCLUSION
The study included 40 patients of post renal transplant anemia (6
month after the renal transplant), and analysis of the nature of anemia
evaluated.
· Only 12.5% of patient had Iron deficiency anemia and 3 patients
(7.5%) had  factors not related to CKD, contributor to the anemia.
· The remaining 80% of the patient had anemia related to the chronic
kidney disease.
· The analysis supported the possibility of the etiopathogenic factors
persisting in the post transplant period, with chronic inflammatory
response.
· The Drugs used predominately in our patients (Cyclosporine,
MMF, Azathioprine, Tacrolimus) are usually known to produce
myelosuppression. Although this could have contributed to the
anemia especially in those patient with low reticlocyte response,
concommitant reduction in leucocyte and platelet counts were not
noted.
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· The concommitant use of anti inflammatory drug including those
with targeted activity - anti IL6 (TOCILIZUMAB) could enhance
the erythropoietin response in hematopoiesis in a majority of
patients.
· With a strong possibility of chronic Inflammatory response
contributing to Refractoriness to erythropoietin mediatated
hemoglobinzation.
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LIMITATIONS
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LIMITATIONS
Ø       Only a small number has been included in our study
Ø CRP is not a sensitive indicator of disease activity
Ø hs CRP which is the better indicator of disease activity could
not be performed in our patients.
Ø Therefore correlative analysis had to be made with serum  LDH
and serum TIBC.  However  a more sensitive indicator would
be Serum IL-6 and Hepcidin levels which have not been done.
Ø Analysis of patients with a higher post transplant period (One
year and above, 2 years and above.......) would provide more
corroborative evidence in this regard.
Ø Patients have not been treated with erythropoietin in our study.
Therefore, resistance to exogenous EPO therapy could not be
evaluated.
Ø Very limited data on post transplant anemia studies is available,
Including studies on Indian patients. Therefore a comparative
analysis could not be made in a comprehensive manner.
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AREAS OF FUTURE RESEARCH
Sequential evaluation of patients in a chronological framework (6
months post transplant, 1 year post transplant, 11/2 years post
transplant......) would help evaluate changes in GFR and also variabilities
in factors influencing post transplant anemia as demonstrated in our study
and also recorded in other similar studies. The chronic inflammatory
activity seems to play an important role in the lack of response to
erythropoietin in these patients with anemia.  Therefore evaluation of IL6
and hepcidin levels in post transplant patient with refractory anemia
would be highly sensitive parameters,  which could also be used as
justification for inclusion of drugs like anti IL6 in the management
strategy.
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PROFORMA
ANEMIA IN POST RENAL TRANSPLANT PATIENTS
Name    : Age : Sex : OP.NO :
Address : Ph.No :
Age at Transplant
Nature kidney disease Dm/SHT/CGN/ADPKD/Others
Comorbid illness
Transplant related information
a. Pre transplant Hb
b. Immunosuppressive drugs
c. Blood loss
d. Graft rejection
e. Other medication
EXAMINATION :
Pallor : Jaundice  :
Lymphadenopathy : Cynaosis :
Clubbing : Pedal edema :
Vital Signs : BP- PR- Temp - RR-
CVS :
RS :
Abdomen :
Genitalia :
Per rectal / per vaginal examination (in females) :
93
INVESTIGATIONS :
CBC
HB% : PCV : ESR : Reticulocyte count :
TC  : P   : L   : E : B : M : Platelets :
Red cell indices   : MCV :      MCH : MCHC : RDW :
Occult Blood in Stools :
Stool for ova & cyst    :
Serum Iron & Feritin
LDH CRP GFR
Serum Erythropoietin
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PATIENT CONSENT FORM
Title :     Anemia in post renal transplant patients
Study centre                     :     Govt.general hospital, MMC,chennai
Patient’s name :
Patient’s age :
Identification number :
 I confirm that I have understood the purpose of the procedures
of   the above study. I have had the opportunity to ask questions and all
my questions have been answered satisfactorily.
           I understand that my participation in the study is entirely
voluntary and that I am free to withdraw from the study at any
time without my legal rights being affected
I understand that sponsors of the study, others working on
sponsor’s behalf, the ethics committee and the regulatory
authorities
will not need my permission to look at my health records both in
respect of current study and any future research that may be
conducted in relation to it; even if I withdraw from the study I
agree to this access. However I understand that my identity will
not be revealed in any information released to third parties unless
required by law. I agree not to restrict the use of any data or
results arising from the study.
I agree to take part in the above the study an to comply with
the instructions given during the study and inform about any
change in my health status to the investigator.
I hereby give permission to undergo complete clinical
examination and investigations as part of the study.
Signature of the patient
Patient’s name and address place
date
Signature of the investigator
Investigator’s name place  date
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MASTER CHART
NAME AGE SEX KD
CO
M
pre
t
Hb
ISD HB PCV MCV
MC
H MCHC TC PLT RC./ PSS IRON TIBC CRP LDH GFR EPO SR.CR
SUDARRAJ 33 M CGN DM 8.5 Y 6 19.6 100 33 34 6400 178,000 1.2 normo normo
poikilo
70 543 neg 300 44 ML 71.6 1.78
KAVITHA 28 F CGN NIL 8.2 Y 7.9 24 98 31 32 4300 178,000 1 hypo micro
poikilo
36.4 965 neg 321 42ML 62.8 2.2
NADIYA 24 F CGN NIL 10 Y 7.8 24 87 27 32 5800 214,000 0.5 nn/hypo micro 73 479 neg 480 32ML 51.9 1.9
NIJAMUDEEN 25 M CGN NIL 8.5 Y 9 26 85 28 34 10,600 60,000 <0.5 hypo micro
poikilo
64.1 335 neg 335 30ML 12.6 2.6
KUMAR 27 M CIN SHT 8.2 Y 8.9 27 84 27 32 14,800 249,000 1.6 nn/hypo 52.3 507 neg 318 62ML 120 1.14
BASKARAN 42 M CIN NIL 9.6 Y 11 30 82 26 31 12,000 291,000 2 micro hypo 50 485 neg 368 61ML 96 1.1
GANESAN 40 M CIN SHT 9 Y 9 30 98 30 30 12,400 278,000 0.8 micro hypo 21.9 753 neg 432 66ML 140 1.2
AMSAR 36 M DM SHT 11 Y 8.7 26 85 27 32 3,900 1.39,000 0.5 micro hypo 53.9 328 neg 454 40ML 17.2 2
MURUGANANDAM 37 M CGN NIL 11.8 Y 10 32 89 29 32 13,200 225,000 1.2 micro hypo 36.4 598 neg 532 63ML 114 1.3
RAMESH 27 M CGN NIL 11 Y 8.7 27 89 28 32 13,200 116,000 1.8 nn/hypo micro 90.3 322 neg 465 30ML 11.9 2.1
VINOTH 42 M DM NIL 9.8 Y 6.6 22 87 26 29 6,800 161,000 0.2 micro hypo 18.8 1201 neg 275 61ML 200 1
VELLUSAMY 37 M CGN NIL 9.8 Y 7.3 23 100 31 31 3,100 78,000 <0.1 normo normo
poikilo
120 1012 neg 324 44ML 4.5 2.8
RAMACHANDRAN 28 M CGN NIL 10 Y 8.9 28.5 86 27 31 10,800 192,000 <0.1 normo normo
poikilo
64 389 neg 303 56ML 82 1.75
MYTHILI 24 M OTH NIL 9.5 Y 6.6 20.4 108 35 32 3,500 264,000 <0.1 nn/macro
normo
102 566 neg 423 70ML 159 1
DHANALAKSMI 27 F CGN NIL 10 Y 6.8 20 94 31 33 4,100 258,000 0.5 nn/micro hypo 93.3 483 neg 324 70ML 25.6 1.27
VALLI 25 F CGN NIL 9.8 Y 6.9 23.4 75 22 29 6,600 252,000 0.5 nn/micro hypo 160 108 neg 324 52ML 54.1 1.2
DHANALAKSMI 30 F CGN NIL 10 Y 6.2 20 84 25 30 6,700 138,000 0.5 nn/micro hypo 52.8 572 neg 298 65ML 13.5 1.1
RAMACHANDRAN 41 F DM NIL 10.3 Y 2.8 7.9 106 37 35 2,500 15,000 <0.5 micro hypo 150 113 neg 262 43ML 200 1.4
JOTHIPRIYA 23 F CGN NIL 11 Y 8 27 105 31 30 6,400 240,000 <0.5 nn/macro
normo
78.7 426 neg 295 69ML 102 1
PALANIVEL 40 M SHT NIL 9 Y 9.2 26 87 27 32 7,400 213,000 <0.5 normo normo
poikilo
78.5 131 neg 324 51ML 60 2.3
MURALITHARAN 37 M CGN NIL 10.8 Y 11 33 79 26 33 4,100 1.74,000 0.4 normo normo
poikilo
71 817 neg 332 37ML 9.6 2
GOPALAKRISHNAN 33 M CGN NIL 9.8 Y 8 26 92 28 30 7,900 1.52,000 <0.5 normo normo
poikilo
126 690 neg 275 44ML 11 3
GANESHAN 42 M DM NIL 11 Y 10 32.7 95 30 31 11,000 160,000 <0.5 normo normo
poikilo
97 960 neg 284 51ML 27.5 1.6
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GANAPATHY 37 M DM NIL 12 Y 10 32 94 32 33 5,300 227,000 1.2 normo normo
poikilo
100 433 neg 234 56ML 66.7 1.4
BALAMURUGAN 27 M CIN NIL 11 Y 11 34 84 27 32 7,700 157,000 0.3 micro hypo 23.5 447 neg 524 56ML 196 1.6
RAGINIKANTH 44 M CIN SHT 10 Y 8.2 31 85 27 32 6,600 209,000 0.8 nn/micro hypo 138 773 neg 532 41ML 36.7 1.6
RENUKA 27 M CIN NIL 9 Y 8 27 74 22 30 4,900 285,000 1.5 micro hypo 42.7 790 neg 623 80ML 21.2 1.1
PRABU 28 M CGN NIL 11 Y 9 28 86 28 32 6,500 227,000 <0.5 nn/micro hypo 77 756 neg 542 40ML 61 1.7
SHANTHI 31 F CIN NIL 9.8 Y 8 25 87 27 31 8,000 162,000 <0.5 nn/micro hypo 191 475 neg 543 47ML 22.7 1.3
KERISHAL 31 M DM NIL 11 Y 7 26 72 19 26 4,600 386,000 1.2 nn/micro hypo 70 646 neg 523 80ML 121 1
VENKATESH 27 M CGN NIL 10 Y 11 30 78 24 31 11,500 187,000 0.8 normo normo
poikilo
128 983 neg 345 44ML 48 1.2
SIVAKUMAR 44 M CGN NIL 9.6 Y 10 30 89 30 33 9,000 2,84.000 1.2 normo normo
poikilo
135 968 neg 423 55ML 50 1.6
RAJASEKAR 28 M CIN NIL 11 Y 11 31 82 29 35 6,600 172,000 0.6 normo normo
poikilo
95 811 neg 523 45ML 45 1.4
PANEERSELVAM 43 M CGN NIL 12 Y 11 33 82 28 32 10,900 242,000 0.8 normo normo
poikilo
161 953 neg 527 48ML 34 1.2
JUDEANTONY 29 M CGN NIL 10 Y 10 32 84 27 32 7,100 166,000 1.6 nn/micro hypo 105 743 neg 612 54ML 42 1.2
PANDI 40 M DM NIL 9 Y 11 33 85 28 33 8,600 109,000 1.2 nn/micro hypo 116 905 neg 687 52ML 44 1.2
RAVI 40 M CGN NIL 10 Y 9 28 87 30 34 8,900 1.84,000 0.8 nn/micro hypo 111 614 neg 324 83ML 66 1
PARITHA 47 F DM NIL 9.8 Y 10.8 33 96 32 33 5,800 187,000 2.1 normo normo
poikilo
61.9 648 48 398 87ML 160 1
PARAMASIVAM 21 M CGN NIL 10 Y 11 33 87 26 33 8,300 160,000 1.2 normo normo
poikilo
163 724 neg 270 55ML 52 1.2
SENTHILKUMAR 37 M CGN NIL 9.1 Y 11 34 87 29 33 7,800 1.51,000 1 normo normo
poikilo
130 565 neg 251 50ML 61 1.1
